Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis
Frontiers in Urology · 17.08.2026 · 6
DOI: 10.3389/fruro.2026.1836469 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Urology, online erschienen am 17.08.2026. Verfasst von Maria Juliana Chaves Medina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Urology Research and Innovation Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Salvage radiotherapy (SRT) is one of the treatment options after progression following surgical management, with effectiveness varying according to patient risk and clinical-pathological characteristics.
Objective
To compare the effectiveness of SRT alone versus SRT combined with androgen deprivation therapy (ADT) in men with biochemical recurrence.
Methods
We conducted a systematic review with advanced searches in MEDLINE (PubMed), EMBASE, SCOPUS, Cochrane CENTRAL, and LILACS for the period 1990–2024. Two independent reviewers performed study selection (titles/abstracts and full text) and data extraction. Risk of bias was assessed with ROBINS-I and RoB 2.0. A random-effects meta-analysis was used to pool effect estimates. PROSPERO registration: CRD42025640604.
Results
Thirteen studies were included. Nine reported overall survival (OS) and biochemical progression-free survival (b-PFS) respectively, four clinical progression-free survival (c-PFS), and eight metastasis-free survival (MFS). Combined SRT+ADT was associated with improved b-PFS (HR 0.51; 95% CI 0.45-0.57; I²=0%) and MFS (HR 0.71; 95% CI 0.60-0.84; I²=39%), whereas the remaining meta-analyzed outcomes showed no consistent benefit or were limited by heterogeneity. Regarding toxicity, the most frequent adverse events were endocrine and sexual, related to hormonal blockade, gynecomastia and erectile dysfunction.
Conclusions
Combined SRT + ADT improves biochemical disease control and may reduce the risk of metastasis in selected patients with biochemical recurrence after radical postatectomy, whereas the effect on overall survival remains uncertain. Individualized management requires risk stratification when deciding on the addition and duration of ADT to optimize oncologic outcomes. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/ , identifier CRD42025640604.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Research and Innovation Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.
- Hospital Universitario Nacional de Colombia, Bogotá, Colombia.
- Urology Unit, Instituto Nacional de Cancerología, Bogotá, Colombia.
- Urology Unit, Department of Surgery, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.
- Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.
Zitieren
APA
Chaves Medina, M. J., Varela Ramírez, R., Donoso Donoso, W., Moreno-Chaparro, J., & Eslava-Schmalbach, J. (2026). Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis. Frontiers in Urology, 6. https://doi.org/10.3389/fruro.2026.1836469
Vancouver
Chaves Medina MJ, Varela Ramírez R, Donoso Donoso W, Moreno-Chaparro J, Eslava-Schmalbach J. Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis. Frontiers in Urology. 2026;6. doi:10.3389/fruro.2026.1836469
BibTeX
@article{ChavesMedina2026,
author = {Chaves Medina, Maria Juliana and Varela Ramírez, Rodolfo and Donoso Donoso, Wilfredo and Moreno-Chaparro, Jaime and Eslava-Schmalbach, Javier},
title = {Use of androgen suppression therapy at salvage radiotherapy in recurrent prostate cancer: a systematic review with meta-analysis},
journal = {Frontiers in Urology},
year = {2026},
volume = {6},
doi = {10.3389/fruro.2026.1836469}
}
EUVIMED